Lupin Ltd
LUPINLupin Ltd
LUPINPrice Chart
How to use scorecard? Learn more
Key Metrics
No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
---|---|---|
44.46 | 7.00 | 0.36% |
Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
---|---|---|
50.66 | 6.47 | 0.51% |
Forecast & Ratings
Detailed Forecast from 32 analysts
Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Lupin Limited is engaged in producing, developing and marketing a range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) across the world.
Peers
Compare with peersSun Pharmaceutical Industries Ltd
Cipla Ltd
Torrent Pharmaceuticals Ltd
Dr Reddy's Laboratories Ltd
Mankind Pharma Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
All values in ₹
All values in ₹
Revenue Forecast
All values in ₹ Thousand cr.
All values in ₹ Thousand cr.
Earnings Per Share Forecast
All values in ₹
All values in ₹
Income
Balance Sheet
Cash Flow
Income Statement
Financial Year | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total Revenue | 14,445.63 | 17,482.14 | 15,950.42 | 15,095.78 | 15,992.56 | 15,300.58 | 16,615.93 | 16,792.57 | 20,141.50 | 20,963.89 | ||||||||||
Raw Materials | 4,778.49 | 5,339.31 | 5,111.62 | 5,150.54 | 5,422.05 | 5,847.10 | 6,679.56 | 6,626.03 | 7,100.91 | 16,603.57 | ||||||||||
Power & Fuel Cost | 381.27 | 377.86 | 433.88 | 442.28 | 443.17 | 414.48 | 443.96 | 479.68 | 493.07 | |||||||||||
Employee Cost | 2,141.62 | 2,849.52 | 2,864.71 | 2,770.17 | 2,986.84 | 2,825.90 | 2,989.30 | 3,087.15 | 3,494.57 | |||||||||||
Selling & Administrative Expenses | 2,369.26 | 2,377.17 | 2,386.87 | 2,513.07 | 2,541.16 | 2,230.63 | 2,490.56 | 2,755.54 | 3,350.98 | |||||||||||
Operating & Other expenses | 899.55 | 1,930.38 | 3,316.31 | 1,567.76 | 2,378.81 | 1,277.97 | 3,583.28 | 1,972.69 | 1,771.28 | |||||||||||
EBITDA | 3,875.44 | 4,607.90 | 1,837.03 | 2,651.96 | 2,220.53 | 2,704.50 | 429.27 | 1,871.48 | 3,930.69 | 4,360.32 | ||||||||||
Depreciation/Amortization | 487.13 | 912.23 | 1,085.87 | 846.05 | 970.22 | 887.41 | 1,658.71 | 880.69 | 1,196.81 | 1,209.86 | ||||||||||
PBIT | 3,388.31 | 3,695.67 | 751.16 | 1,805.91 | 1,250.31 | 1,817.09 | -1,229.44 | 990.79 | 2,733.88 | 3,150.46 | ||||||||||
Interest & Other Items | 59.47 | 152.53 | 204.35 | 302.49 | 362.98 | 140.64 | 142.77 | 274.30 | 311.61 | 293.95 | ||||||||||
PBT | 3,328.84 | 3,543.14 | 546.81 | 1,503.42 | 887.33 | 1,676.45 | -1,372.21 | 716.49 | 2,422.27 | 2,856.51 | ||||||||||
Taxes & Other Items | 1,068.10 | 985.68 | 295.55 | 896.87 | 1,156.72 | 459.92 | 155.83 | 286.41 | 507.79 | 592.98 | ||||||||||
Net Income | 2,260.74 | 2,557.46 | 251.26 | 606.55 | -269.39 | 1,216.53 | -1,528.04 | 430.08 | 1,914.48 | 2,263.53 | ||||||||||
EPS | 50.23 | 56.70 | 5.56 | 13.41 | -5.95 | 26.83 | -33.65 | 9.46 | 42.05 | 49.67 | ||||||||||
DPS | 7.50 | 7.50 | 5.00 | 5.00 | 6.00 | 6.50 | 4.00 | 4.00 | 8.00 | 4.00 | ||||||||||
Payout ratio | 0.15 | 0.13 | 0.90 | 0.37 | — | 0.24 | — | 0.42 | 0.19 | 0.08 |
Company Updates
Annual report
PDFPeers & Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
---|---|---|---|
Lupin Ltd | 52.57 | 7.00 | 0.36% |
Sun Pharmaceutical Industries Ltd | 46.89 | 6.69 | 0.72% |
Cipla Ltd | 28.95 | 4.45 | 0.88% |
Torrent Pharmaceuticals Ltd | 65.70 | 15.87 | 0.87% |
Price Comparison
Compare LUPIN with any stock or ETFShareholdings
Promoter Holdings Trend
Total Promoter Holding
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Pledged promoter holdings is insignificant
Institutional Holdings Trend
Total Retail Holding
In last 3 months, retail holding in the company has almost stayed constant
Increased Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has increased by 2.18%
Shareholding Pattern
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Shareholding History
Mutual Funds Holding Trend
Mutual Fund Holding
In last 3 months, mutual fund holding of the company has almost stayed constant
Top 5 Mutual Funds holding Lupin Ltd
Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
---|---|---|---|---|
HDFC Balanced Advantage Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 1.2590% | Percentage of the fund’s portfolio invested in the stock 1.31% | Change in the portfolio weight of the stock over the last 3 months 0.27% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 14/301 (+4) |
HDFC Top 100 Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.7335% | Percentage of the fund’s portfolio invested in the stock 1.91% | Change in the portfolio weight of the stock over the last 3 months 0.37% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 30/51 (0) |
Nippon India Pharma Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.6879% | Percentage of the fund’s portfolio invested in the stock 8.01% | Change in the portfolio weight of the stock over the last 3 months 0.33% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 3/36 (0) |
Compare 3-month MF holding change on Screener
smallcases
A smallcase is a basket of stocks/ETFs that represents an idea or theme.Diversify your risk and buy smallcases that have Lupin Ltd
Events
Dividend Trend
No Trend In Dividends
LUPIN has shown inconsistent dividend trend over the last 5 years
Dividend Yield
Current dividend yield is 0.36%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹3.62 every year
Dividends
Corp. Actions
Announcements
Legal Orders
Upcoming Dividends
No upcoming dividends are available
Past Dividends
Cash Dividend
Ex DateEx DateJul 16, 2024
Dividend/Share
₹8.00
Ex DateEx Date
Jul 16, 2024
Cash Dividend
Ex DateEx DateJul 14, 2023
Dividend/Share
₹4.00
Ex DateEx Date
Jul 14, 2023
Cash Dividend
Ex DateEx DateJul 14, 2022
Dividend/Share
₹4.00
Ex DateEx Date
Jul 14, 2022
Cash Dividend
Ex DateEx DateJul 27, 2021
Dividend/Share
₹6.50
Ex DateEx Date
Jul 27, 2021
Cash Dividend
Ex DateEx DateAug 3, 2020
Dividend/Share
₹6.00
Ex DateEx Date
Aug 3, 2020
Lupin Ltd gained for a third straight session today. The stock is quoting at Rs 2205.2, up 2.25% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 1.01% on the day, quoting at 24425.65. The Sensex is at 80274.05, up 1.1%. Lupin Ltd has gained around 0.64% in last one month. Meanwhile, Nifty Pharma index of which Lupin Ltd is a constituent, has gained around 2.07% in last one month and is currently quoting at 22574.55, up 1% on the day. The volume in the stock stood at 9.05 lakh shares today, compared to the daily average of 9.34 lakh shares in last one month. The benchmark October futures contract for the stock is quoting at Rs 2205.05, up 2.17% on the day. Lupin Ltd is up 93.38% in last one year as compared to a 27.61% jump in NIFTY and a 54.31% jump in the Nifty Pharma index.The PE of the stock is 35.89 based on TTM earnings ending June 24.Powered by Capital Market - Live
Lupin has allotted 51,609 equity shares under ESOP on 23 October 2024. The issued and paid-up capital of the Company has been increased to Rs 91,23,89,842 consisting of 45,61,94,921 equity shares of Rs 2/- each.Powered by Capital Market - Live
Lupin will hold a meeting of the Board of Directors of the Company on 7 November 2024.Powered by Capital Market - Live
Being the first generic to be approved and launched, the company is entitled to 180-day competitive generic therapy (CGT) exclusivity. Prednisolone Acetate Ophthalmic Suspension is a generic equivalent of Pred Forte Ophthalmic Suspension of AbbVie, Inc. It is indicated for the treatment of steroid-responsive inflammation of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe. Pred Forte had estimated annual sales of $198 million in the U.S., IQVIA MAT August 2024. Vinita Gupta, CEO, Lupin, said: 'The launch of Prednisolone Acetate Ophthalmic Suspension is a milestone and is aligned with our commitment to enhancing access to innovative, affordable and quality healthcare solutions. This will strengthen our ophthalmic portfolio and will benefit patients seeking effective treatment for steroid-responsive inflammation.' Mumbai-based Lupin is an innovation-led transnational pharmaceutical company. It develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S, India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions. The company's consolidated net profit jumped 76.01% to Rs 801.31 crore during the quarter as compared with Rs 452.26 crore posted in Q1 FY24. Revenue from operations increased 16.28% YoY to Rs 5,514.34 crore during the quarter. Powered by Capital Market - Live
Lupin announced the launch of the first generic version of Pred Forte' (Prednisolone Acetate) Ophthalmic Suspension USP, 1% in the United States. Being the first generic to be approved and launched, the company is entitled to 180-day competitive generic therapy (CGT) exclusivity. Prednisolone Acetate Ophthalmic Suspension USP, 1% is a generic equivalent of Pred Forte' Ophthalmic Suspension, 1% of AbbVie, Inc. and is indicated for the treatment of steroid responsive inflammation of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe. Pred Forte' had estimated annual sales of USD 198 million in the U.S. (IQVIA MAT August 2024). Powered by Capital Market - Live
The inspection was carried out from 25 September 2024 to 04 October 2024, and concluded with five observations. The company is addressing the observations comprehensively and will respond to the U.S. FDA within the stipulated timeframe. Mumbai-based Lupin is an innovation-led transnational pharmaceutical company. It develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S, India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions. The company's consolidated net profit jumped 76.01% to Rs 801.31 crore during the quarter as compared with Rs 452.26 crore posted in Q1 FY24. Revenue from operations increased 16.28% YoY to Rs 5,514.34 crore during the quarter. The scrip had advanced 0.65% to end at Rs 2197.60 on the BSE on Friday. Powered by Capital Market - Live
The inspection concluded with 3 observations on both the API and Finished Product sides. The pharmaceutical major is addressing these observations comprehensively and will respond to the USFDA within the stipulated timeframe. Mumbai-based Lupin is an innovation-led transnational pharmaceutical company. It develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S, India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions. The company's consolidated net profit jumped 76.01% to Rs 801.31 crore during the quarter as compared with Rs 452.26 crore posted in Q1 FY24. Revenue from operations increased 16.28% YoY to Rs 5,514.34 crore during the quarter. Shares of Lupin gained 1.56% to end at Rs 2,221.50 on Friday, 27 September 2024. Powered by Capital Market - Live
Lupin informed that the U.S. FDA inspected Lupin's Pithampur Unit-1 API and finished product manufacturing facility from 16 September to 27 September 2024. The inspection closed with three observations each on the API and Finished Product side.Powered by Capital Market - Live
Lupin has allotted 5,893 equity shares under ESOP on 20 September 2024. Post allotment, the issued and paid-up capital of the Company has been increased to Rs 91,22,86,624 consisting of 45,61,43,312 equity shares of Rs 2/- each.Powered by Capital Market - Live
Vonoprazan is a novel potassium-competitive acid blocker (P-CAB). Unlike traditional acid suppressants like PPIs, Vonoprazan offers unique attributes like complete proton pump inhibition with the first dose, longer duration of action resulting in effective control of nocturnal acid breakthrough and meal-independent dosing. In India, Vonoprazan is approved by the Drug Controller General of India (DCGI) for treating reflux esophagitis, gastric ulcers, duodenal ulcers, and as part of Helicobacter pylori eradication treatment. The said drug will be marketed under the brand name Lupin's Lupivon and will be available in two strengths 10 mg and 20 mg. Under the terms of this agreement, Takeda has granted Lupin non-exclusive patent licensing rights to commercialize Vonoprazan in India. Rajeev Sibal, president India region formulations, Lupin,We are very pleased to commercialize Vonoprazan, a novel treatment option for Acid Peptic Disorders. This is a further step in strengthening our gastroenterology portfolio and is in line with our commitment to introduce innovative medicines to address unmet needs of our patients.' Mumbai-based Lupin is an innovation-led transnational pharmaceutical company. It develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S, India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions. The company's consolidated net profit jumped 76.01% to Rs 801.31 crore during the quarter as compared with Rs 452.26 crore posted in Q1 FY24. Revenue from operations increased 16.28% YoY to Rs 5,514.34 crore during the quarter. The scrip declined 2.32% to Rs 2,217.85Powered by Capital Market - Live
Lower than Industry Revenue Growth
Over the last 5 years, revenue has grown at a yearly rate of 5.94%, vs industry avg of 9.03%
Decreasing Market Share
Over the last 5 years, market share decreased from 6.88% to 5.34%
Higher than Industry Net Income
Over the last 5 years, net income has grown at a yearly rate of 25.85%, vs industry avg of 15.28%